HER2-targeted drug-resistant cancer cells correlate with increased levels of immunosuppressive molecules such as transforming growth factor-beta 1 (TGFβ1) and programmed cell death ligand 1 (PD-L1), causing resistance to the anti-tumor immune response. Here, ERBB2 is linked to cancer.